Argireline (Acetyl Hexapeptide-3)
Also known as: Acetyl Hexapeptide-3, AcHex-8, Argirelin, SNAP-8 predecessor
Overview
Argireline (acetyl hexapeptide-3) is a synthetic hexapeptide inspired by the N-terminal sequence of SNAP-25, a SNARE complex protein involved in neuromuscular junction signaling. By competing with SNAP-25 for SNARE complex assembly, Argireline reduces neurotransmitter release at neuromuscular junctions and thereby attenuates the repetitive facial muscle contractions that generate dynamic expression lines. Often called 'botox in a cream,' it is one of the top-selling peptide cosmeceuticals globally with clinical evidence for wrinkle reduction.
Mechanism of Action
Argireline's sequence (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) mimics the N-terminal residues 12-17 of SNAP-25. It competes with native SNAP-25 for incorporation into the ternary SNARE complex (SNAP-25/syntaxin/synaptobrevin). Partial disruption of SNARE assembly reduces vesicular fusion efficiency at neuromuscular junctions, lowering acetylcholine release and reducing muscle fiber contraction frequency and strength. This is mechanistically similar to botulinum toxin but the effect is partial and reversible, with no neurotoxic activity.
Potential Benefits
- Reduction of dynamic expression wrinkles (crow's feet, forehead lines)
- Non-invasive alternative or complement to botulinum toxin
- Improved skin smoothness in clinical studies
- Combination benefit with moisturizers and other cosmeceutical peptides
- Well-tolerated with no systemic effects
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 5% Argireline serum 1x daily |
| Intermediate | 10% Argireline serum 2x daily |
| Advanced | 10% Argireline + other SNAP peptides (SNAP-8) combination |
| Cycle Duration | Continuous cosmetic use; effects at 4-8 weeks |
Acetyl hexapeptide-3/8 — SNARE-complex modulator. 'Topical Botox' marketing — effects modest.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Topical (serum/cream) Limited penetration — effects superficial
Apply to expression lines (forehead, crow's feet, glabella).
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Argireline (Acetyl Hexapeptide-3):
Expression Line Stack
Multi-peptide SNARE inhibition + collagen stimulation for expression-line reduction.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store at room temperature, away from light and heat |
|---|
Topical/cosmetic peptide — comes pre-formulated. No reconstitution needed.
Need exact syringe measurements?
Amino Acid Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
Side Effects & Safety
- Well-tolerated topically
- Rare skin irritation at high concentrations
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store cream/serum at room temperature away from direct sunlight and heat. Refrigeration optional to extend shelf life. |
Synergistic Compounds
The following compounds have been studied alongside Argireline (Acetyl Hexapeptide-3) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.